GH vs. REGN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at GH and REGN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | GH | REGN |
|---|---|---|
| Company Name | Guardant Health, Inc. | Regeneron Pharmaceuticals, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Biotechnology |
| Market Capitalization | 12.45 billion USD | 74.98 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | October 4, 2018 | April 2, 1991 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of GH and REGN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | GH | REGN |
|---|---|---|
| 5-Day Price Return | -3.63% | 5.92% |
| 13-Week Price Return | 60.28% | 19.48% |
| 26-Week Price Return | 128.17% | 20.79% |
| 52-Week Price Return | 198.54% | -13.78% |
| Month-to-Date Return | 1.45% | 6.40% |
| Year-to-Date Return | 208.90% | -2.64% |
| 10-Day Avg. Volume | 3.33M | 0.97M |
| 3-Month Avg. Volume | 2.71M | 1.03M |
| 3-Month Volatility | 68.73% | 37.82% |
| Beta | 1.63 | 0.39 |
Profitability
Return on Equity (TTM)
GH
-246.60%
Health Care Providers & Services Industry
- Max
- 24.67%
- Q3
- 15.54%
- Median
- 8.37%
- Q1
- 5.49%
- Min
- -2.09%
GH has a negative Return on Equity of -246.60%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
REGN
15.31%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
In the upper quartile for the Biotechnology industry, REGN’s Return on Equity of 15.31% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
GH
-44.18%
Health Care Providers & Services Industry
- Max
- 9.33%
- Q3
- 4.80%
- Median
- 2.90%
- Q1
- 0.93%
- Min
- -3.28%
GH has a negative Net Profit Margin of -44.18%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
REGN
32.13%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
A Net Profit Margin of 32.13% places REGN in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
GH
-48.05%
Health Care Providers & Services Industry
- Max
- 18.35%
- Q3
- 8.71%
- Median
- 5.10%
- Q1
- 2.10%
- Min
- -3.07%
GH has a negative Operating Profit Margin of -48.05%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
REGN
25.89%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
An Operating Profit Margin of 25.89% places REGN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | GH | REGN |
|---|---|---|
| Return on Equity (TTM) | -246.60% | 15.31% |
| Return on Assets (TTM) | -29.33% | 11.91% |
| Net Profit Margin (TTM) | -44.18% | 32.13% |
| Operating Profit Margin (TTM) | -48.05% | 25.89% |
| Gross Profit Margin (TTM) | 63.76% | 86.28% |
Financial Strength
Current Ratio (MRQ)
GH
3.50
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.56
- Median
- 1.28
- Q1
- 0.92
- Min
- 0.01
GH’s Current Ratio of 3.50 is exceptionally high, placing it well outside the typical range for the Health Care Providers & Services industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.
REGN
4.06
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
REGN’s Current Ratio of 4.06 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
GH
16.78
Health Care Providers & Services Industry
- Max
- 2.41
- Q3
- 1.39
- Median
- 0.74
- Q1
- 0.46
- Min
- 0.00
With a Debt-to-Equity Ratio of 16.78, GH operates with exceptionally high leverage compared to the Health Care Providers & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
REGN
0.09
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
REGN’s Debt-to-Equity Ratio of 0.09 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
GH
-150.95
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.46
- Median
- 4.52
- Q1
- 2.04
- Min
- -4.44
GH has a negative Interest Coverage Ratio of -150.95. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
REGN
49.98
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
REGN’s Interest Coverage Ratio of 49.98 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | GH | REGN |
|---|---|---|
| Current Ratio (MRQ) | 3.50 | 4.06 |
| Quick Ratio (MRQ) | 2.94 | 3.38 |
| Debt-to-Equity Ratio (MRQ) | 16.78 | 0.09 |
| Interest Coverage Ratio (TTM) | -150.95 | 49.98 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
GH
0.00%
Health Care Providers & Services Industry
- Max
- 5.51%
- Q3
- 2.66%
- Median
- 1.06%
- Q1
- 0.00%
- Min
- 0.00%
GH currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
REGN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
GH
0.00%
Health Care Providers & Services Industry
- Max
- 187.56%
- Q3
- 81.14%
- Median
- 33.42%
- Q1
- 0.00%
- Min
- 0.00%
GH has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
REGN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | GH | REGN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
GH
--
Health Care Providers & Services Industry
- Max
- 48.86
- Q3
- 32.22
- Median
- 21.78
- Q1
- 13.97
- Min
- 8.01
P/E Ratio data for GH is currently unavailable.
REGN
15.92
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
REGN’s P/E Ratio of 15.92 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
GH
13.74
Health Care Providers & Services Industry
- Max
- 3.66
- Q3
- 1.64
- Median
- 0.72
- Q1
- 0.27
- Min
- 0.10
With a P/S Ratio of 13.74, GH trades at a valuation that eclipses even the highest in the Health Care Providers & Services industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
REGN
5.12
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
REGN’s P/S Ratio of 5.12 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
GH
35.72
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.33
- Median
- 2.48
- Q1
- 1.31
- Min
- 0.65
At 35.72, GH’s P/B Ratio is at an extreme premium to the Health Care Providers & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
REGN
1.93
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
REGN’s P/B Ratio of 1.93 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | GH | REGN |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 15.92 |
| Price-to-Sales Ratio (TTM) | 13.74 | 5.12 |
| Price-to-Book Ratio (MRQ) | 35.72 | 1.93 |
| Price-to-Free Cash Flow Ratio (TTM) | -- | 18.78 |